|
Interferon alfa and Thalidomide in Treating Patients With Soft Tissue Sarcoma or Bone Sarcoma Clinical Trials Resources presented on Clinical Trials Search isn't meant to be a substitute for qualified health advice, visits or professional assistance with a real medical. We aren't doctors. Always consult your mD about Interferon alfa and Thalidomide in Treating Patients With Soft Tissue Sarcoma or Bone Sarcoma conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Interferon alfa and Thalidomide in Treating Patients With Soft Tissue Sarcoma or Bone Sarcoma Clinical research trials and Interferon alfa and Thalidomide in Treating Patients With Soft Tissue Sarcoma or Bone Sarcoma health trials occur in a lot of of places throughout the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectivity of new does drugs. The role of the studies / projects is to resolve certain human healthcare questions. Clinical trials are a popular way for doctors, government agencies, and private sector corporations to detect remedies for all varieties of circumstances, such as Interferon alfa and Thalidomide in Treating Patients With Soft Tissue Sarcoma or Bone Sarcoma. Interferon alfa and Thalidomide in Treating Patients With Soft Tissue Sarcoma or Bone Sarcoma Clinical Trials and other clinical trials allow volunteers to obtain health treatment choices before they are available to the general public. Most times the human subjects recieve professional assistance for free of charge, and every now and again they are paid for their time. Sometimes there is a cost for a Interferon alfa and Thalidomide in Treating Patients With Soft Tissue Sarcoma or Bone Sarcoma clinical trial. Human subjects frequently get the finest healthcare available for their Interferon alfa and Thalidomide in Treating Patients With Soft Tissue Sarcoma or Bone Sarcoma condition. Risks are a reality, however, and may include extra or frequent physician visits, medical dangers (possibly life-threatening), and/or the treatment being uneffective. Trials are federally governed with strict guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "I" Clinical Trials Conditions > Interferon alfa and Thalidomide in Treating Patients With Soft Tissue Sarcoma or Bone Sarcoma  Interferon alfa and Thalidomide in Treating Patients With Soft Tissue Sarcoma or Bone Sarcoma
Interferon alfa and Thalidomide in Treating Patients With Soft Tissue Sarcoma or Bone Sarcoma
For Condition: stage 4A adult soft tissue sarcoma,stage 3 adult soft tissue sarcoma,stage 4B adult soft tissue sarcoma,localized osteosarcoma,stage 2C adult soft tissue sarcoma,metastatic osteosarcoma
Status: No longer recruiting
Sponsor(s): Herbert Irving Comprehensive Cancer Center , National Cancer Institute (NCI)
Synopsis: RATIONALE: Thalidomide may stop the growth of cancer by stopping blood flow to the tumor. Interferon alfa may interfere with the growth of cancer cells. Combining interferon alfa and thalidomide may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining interferon alfa and thalidomide in treating patients who have undergone surgery for soft tissue sarcoma or bone sarcoma.
Details: OBJECTIVES: - Determine the efficacy of interferon alfa and thalidomide, in terms of time to disease progression, in patients with surgically resected high-risk soft tissue sarcoma or bone sarcoma. - Determine the incidence of metastatic disease and overall survival in patients treated with this regimen. - Determine the clinical and laboratory toxic effects and the tolerability of this regimen in these patients. OUTLINE: Patients receive interferon alfa subcutaneously three times a week on weeks 1-60 and oral thalidomide once daily on weeks 13-60 in the absence of disease progression or unacceptable toxicity. Patients are followed every 6 weeks for at least 2 years. PROJECTED ACCRUAL: A total of 20-48 patients will be accrued for this study.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Histologically confirmed primary or metastatic soft tissue sarcoma or bone sarcoma at high risk of recurrence - Grade III-IV tumor greater than 8 cm - Grade III-IV primary tumor greater than 5 cm with positive surgical margins - Grade III-IV primary tumor greater than 5 cm with distant metastases resected within 1 year of primary surgery - No more than 8 weeks since prior surgical resection of primary or metastatic disease - Ineligible for other high priority national or institutional study PATIENT CHARACTERISTICS: Age: - 18 and over Performance status: - SWOG 0-2 Life expectancy: - More than 2 months Hematopoietic: - WBC greater than 3,000/mm^3 - Neutrophil count at least 1,500/mm^3 - Platelet count greater than 70,000/mm^3 - Hemoglobin at least 10.0 g/dL Hepatic: - Bilirubin less than 2.0 mg/dL - SGOT or SGPT less than 3 times upper limit of normal (ULN)* - Alkaline phosphatase less than 3 times ULN* - No decompensated liver disease - No autoimmune hepatitis - No coagulation disorders NOTE: * Unless due to metastatic disease Renal: - Creatinine normal Cardiovascular: - No history of severely debilitating cardiovascular disease - No unstable angina - No uncontrolled congestive heart failure - No thrombophlebitis Pulmonary: - No history of severely debilitating pulmonary disease - No chronic obstructive pulmonary disease - No pulmonary embolism Other: - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use 2 forms of effective contraception for 4 weeks before, during, and for 4 weeks after study - No acute infection requiring systemic antibiotics - No prior hypersensitivity to interferon alfa or any component of the injection - No diabetes mellitus prone to ketoacidosis - No severe myelosuppression - No history of autoimmune disease - No pre-existing thyroid abnormalities with thyroid function that cannot be maintained in the normal range - No clinically significant retinal abnormalities - No other serious medical or psychiatric illness that would preclude study - No prior malignancy except curatively treated carcinoma in situ of the cervix or skin cancer PRIOR CONCURRENT THERAPY: Biologic therapy: - Not specified Chemotherapy: - Prior systemic chemotherapy allowed Endocrine therapy: - Not specified Radiotherapy: - Prior radiotherapy allowed Surgery: - See Disease Characteristics
Total Enrollment:
Location and Contact Information:
Overall Study Official:
RobertTaub, Study Chair, Columbia Presbyterian Medical Center
Herbert Irving Comprehensive Cancer Center
New York City, New York, 10032
United States
Additional Information:
Study ID Numbers: CDR0000069028; NCI-G01-2024,CPMC-IRB-13887
Study Start Date:
Record last reviewed: November 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00026416
Other Stage 3 Adult Soft Tissue Sarcoma Studies:
1. Inhaled Sargramostim in Treating Patients With First Pulmonary (Lung) Recurrence of Osteosarcoma
2. Bortezomib in Treating Patients With Advanced or Metastatic Sarcoma
3. Neoadjuvant and Adjuvant Pamidronate With Induction and Maintenance Chemotherapy in Treating Patients With Osteosarcoma
4. Combination Chemotherapy and Radiation Therapy in Treating Patients With Peripheral Neuroectodermal Tumors, Ewing's Sarcoma, Wilms' Tumor, or Bone Cancer
5. Interferon alfa and Thalidomide in Treating Patients With Soft Tissue Sarcoma or Bone Sarcoma
Related Studies:
Other stage 3 adult soft tissue sarcoma Clinical Trials
Other New York Clinical Trials
Other New York City Clinical Trials
Interferon alfa and Thalidomide in Treating Patients With Soft Tissue Sarcoma or Bone Sarcoma
|
|
|
|
|
|
|
|
